CELZ Stock Overview
A commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Creative Medical Technology Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.96 |
| 52 Week High | US$10.28 |
| 52 Week Low | US$2.65 |
| Beta | 5.04 |
| 11 Month Change | -14.94% |
| 3 Month Change | -22.00% |
| 1 Year Change | -38.97% |
| 33 Year Change | -96.05% |
| 5 Year Change | -99.55% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| CELZ | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.6% | -0.2% | -0.4% |
| 1Y | -39.0% | 22.1% | 34.1% |
Return vs Industry: CELZ underperformed the US Biotechs industry which returned 22.1% over the past year.
Return vs Market: CELZ underperformed the US Market which returned 34.1% over the past year.
Price Volatility
| CELZ volatility | |
|---|---|
| CELZ Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CELZ's share price has been volatile over the past 3 months.
Volatility Over Time: CELZ's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 4 | Tim Warbington | www.creativemedicaltechnology.com |
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure.
Creative Medical Technology Holdings, Inc. Fundamentals Summary
| CELZ fundamental statistics | |
|---|---|
| Market cap | US$4.04m |
| Earnings (TTM) | -US$5.73m |
| Revenue (TTM) | US$17.00k |
233.0x
P/S Ratio-0.7x
P/E RatioIs CELZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CELZ income statement (TTM) | |
|---|---|
| Revenue | US$17.00k |
| Cost of Revenue | US$6.80k |
| Gross Profit | US$10.20k |
| Other Expenses | US$5.74m |
| Earnings | -US$5.73m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.28 |
| Gross Margin | 60.00% |
| Net Profit Margin | -33,716.46% |
| Debt/Equity Ratio | 0.2% |
How did CELZ perform over the long term?
See historical performance and comparison